Growth Hormone (GH) Agonist - Pipeline Insight 2018 - ResearchAndMarkets.com

December 21, 2018

DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The “Growth Hormone (GH) Agonist -Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.

Growth Hormone (GH) Agonist - Pipeline Insight, 2018′ report offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Growth Hormone (GH) Agonist development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.

Pipeline Products covered across the following Developmental Stages:

Clinical Non-clinical Inactive: Discontinued and/or Dormant

Descriptive coverage of pipeline development activities for Growth Hormone (GH) Agonist - Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.

Key Topics Covered:

1. Report Introduction

2. Growth Hormone (GH) Agonist - Overview

3. Pipeline Therapeutics

4. Comparative Analysis

5. Growth Hormone (GH) Agonist Pipeline Products in Clinical Stages

6. Growth Hormone (GH) Agonist Pipeline Products in Non-clinical Stages

7. Therapeutic Assessment: Active Products

8. Inactive Pipeline Products

Companies Mentioned

Pfizer Teva Pharmaceutical Industries OPKO Health Merck Serono Novo Nordisk Hanmi Pharmaceutical HanAll Biopharma JCR Pharmaceuticals Savient Pharmaceuticals Genexine Critical Pharmaceuticals Ascendis Pharma Peptor

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/hw66qc/growth_hormone?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005307/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 12/21/2018 10:03 AM/DISC: 12/21/2018 10:03 AM


Update hourly